Eyepoint Pharmaceuticals, Inc. 8-K Filing
Ticker: EYPT · Form: 8-K · Filed: May 6, 2024 · CIK: 1314102
| Field | Detail |
|---|---|
| Company | Eyepoint Pharmaceuticals, Inc. (EYPT) |
| Form Type | 8-K |
| Filed Date | May 6, 2024 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Eyepoint Pharmaceuticals, Inc. (ticker: EYPT) to the SEC on May 6, 2024.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ch registered Common Stock, par value $0.001 EYPT The Nasdaq Global Market Ind).
How long is this filing?
Eyepoint Pharmaceuticals, Inc.'s 8-K filing is 2 pages with approximately 480 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 480 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-05-06 09:25:17
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 EYPT The Nasdaq Global Market Ind
Filing Documents
- eypt-20240506.htm (8-K) — 40KB
- eypt-ex99_1.htm (EX-99.1) — 36KB
- eypt-ex99_2.htm (EX-99.2) — 18KB
- img96707757_0.jpg (GRAPHIC) — 5KB
- eypt-ex99_2s1.jpg (GRAPHIC) — 244KB
- eypt-ex99_2s2.jpg (GRAPHIC) — 815KB
- eypt-ex99_2s3.jpg (GRAPHIC) — 532KB
- eypt-ex99_2s4.jpg (GRAPHIC) — 427KB
- eypt-ex99_2s5.jpg (GRAPHIC) — 460KB
- eypt-ex99_2s6.jpg (GRAPHIC) — 486KB
- eypt-ex99_2s7.jpg (GRAPHIC) — 210KB
- eypt-ex99_2s8.jpg (GRAPHIC) — 451KB
- eypt-ex99_2s9.jpg (GRAPHIC) — 282KB
- eypt-ex99_2s10.jpg (GRAPHIC) — 372KB
- eypt-ex99_2s11.jpg (GRAPHIC) — 264KB
- eypt-ex99_2s12.jpg (GRAPHIC) — 260KB
- eypt-ex99_2s13.jpg (GRAPHIC) — 281KB
- eypt-ex99_2s14.jpg (GRAPHIC) — 275KB
- eypt-ex99_2s15.jpg (GRAPHIC) — 398KB
- eypt-ex99_2s16.jpg (GRAPHIC) — 522KB
- eypt-ex99_2s17.jpg (GRAPHIC) — 240KB
- 0000950170-24-053248.txt ( ) — 9198KB
- eypt-20240506.xsd (EX-101.SCH) — 23KB
- eypt-20240506_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On May 6, 2024, EyePoint Pharmaceuticals, Inc. (the "Company") issued a press release announcing results for its Phase 2 PAVIA clinical trial for the potential treatment of moderately-severe to severe non-proliferative diabetic retinopathy (NPDR). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. Additionally, on May 6, 2024, the Company posted an updated investor presentation on its website at www.eyepointpharma.com. A copy of the presentation is filed herewith as Exhibit 99.2 and is incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of EyePoint Pharmaceuticals, Inc. dated May 06, 2024 99.2 Investor Presentation of EyePoint Pharmaceuticals, Inc. dated May 06, 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EYEPOINT PHARMACEUTICALS, INC. Date: May 6, 2024 By: /s/ George O. Elston George O. Elston Executive Vice President and Chief Financial Officer